Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide
| Autor: | Jennifer Maitland, Garry Forgeson, Glen Goss, Ray Powles, Timothy J. Perren, Martin Gore, Sarah Milan, Jennifer Treleaven, A Nandi, Fulvio Porta, Ayed Zuiable, Anil Lakhani |
|---|---|
| Rok vydání: | 1989 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Anthracycline medicine.drug_class medicine.medical_treatment Toxicology Antimetabolite Gastroenterology Refractory Recurrence hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols Medicine Humans Pharmacology (medical) Etoposide Bone Marrow Transplantation Pharmacology Chemotherapy business.industry Cytarabine Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Surgery Transplantation Leukemia Leukemia Myeloid Acute Oncology Female business medicine.drug |
| Zdroj: | Cancer chemotherapy and pharmacology. 23(6) |
| ISSN: | 0344-5704 |
| Popis: | A total of 65 patients under the age of 55 with acute leukaemia received high-dose cytosine arabinoside (Ara-C) in combination with high-dose etoposide without an anthracycline. Complete remission rates for patients with relapsed or refractory acute myelogenous leukaemia (AML) were 15/25 (60%) and 11/16 (69%), respectively. The complete remission rate for patients with refractory or relapsed acute lymphoblastic leukaemia (ALL) was 10/18 (56%). The treatment-related mortality was 17%. Nine patients whose leukaemia relapsed after matched allogeneic, sibling bone-marrow transplantation (BMT) were also treated in this way; the treatment-related mortality in this group was high (7/9) and the duration of remission in the two patients who responded, too short to justify this intensive treatment in such patients. Similarly, patients who underwent BMT after achieving a complete remission with high-dose Ara-C and etoposide did very poorly, only one patient surviving well and disease-free at 8 months. The important finding in this study was the high complete remission rate rapidly obtained in patients with relapsed or refractory AML without using an anthracycline. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink